Navigation Links
Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens' Hospital
Date:2/26/2008

EMERYVILLE, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced the amendment of its license and cooperation agreement with Merz Pharmaceuticals GmbH (Merz) and Childrens' Medical Center Corporation ("CMCC") relating to memantine, which is currently marketed in the United States as Namenda(TM) and in Europe as Ebixa(TM).

The amendment modifies the terms of the royalties to be paid to the company on sales of memantine, including discontinuing the payment of royalties on sales of memantine for Alzheimer's disease outside of the United States beginning in the fourth quarter of 2007 (for which the company is due to receive a royalty payment in April 2008) and providing for a staged reduction in the royalty rates to be paid to the company and CMCC on sales of memantine in the United States beginning in the third quarter of 2008. In addition, the amendment provides that neither CMCC nor Merz will give notice of termination of the agreement under the section relating to the development of memantine for the CMCC indications before July 1, 2009 or to be effective before January 1, 2010.

"We felt it was important to agree to this amendment to reduce the uncertainty relating to ability of Merz and CMCC to terminate the agreement on six months' notice and to give us greater assurance that we will continue to receive royalty payments on US sales of memantine for at least the next two years, which will be a critical period for our company as we complete our pivotal phase 3 clinical trials of Viprinex(TM) for ischemic stroke," said Paul E. Freiman, President and CEO of Neurobiological Technologies. "As we effectively receive our payments two quarters after the memantine sale
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
2. Neurobiological Technologies Sets Date for Research and Development Day
3. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
4. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
5. Neurobiological Technologies Sets Date for Second Quarter Financial Results
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
8. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
9. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
10. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
11. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... laboratory information management systems market is a rapidly growing ... due to factors such as rising pressure to comply ... and increasing government support for adoption of HCIT solutions ... the market focus on technological advancements to further the ...
(Date:1/22/2015)... 2015 Dr. Greg Leyer of UAS Labs ... Natural Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... continuing education conference for health care professionals. This year’s pre-conference ... of probiotics in health. Dr. Leyer spoke about the emerging ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... WOBURN, Mass., Nov. 26 Covaris Incorporated today,announced that ... shipment,of its 500th instrument unit and continued another successful ... Covaris is both,strengthening its sales and marketing organization as ... , The Covaris ...
... TOKYO and CAMBRIDGE, England, November 26 Sosei,Group Corporation ... that it has out-licensed its IP and Know How,relating ... ("Treague"), a,Cambridge, UK based pharma company, for the treatment ... Mefloquine is a highly efficacious anti-malarial drug that ...
... ANDS ) announced today that it will present at ... 3, 2008 at 9:30 a.m. EST (6:30 a.m. PST) at the ... Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will ... ANA598 and ANA773 in hepatitis C and ANA773 in cancer. , ...
Cached Biology Technology:Covaris Installed Instrument Base Reaches 500 Units 2Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria 2Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference 2
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB SM ... (GCP) audit to confirm its adherence to current U.S. ... HITLAB to conduct regulated smart device and smart phone ... and research quality. "HITLAB is determined to ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming ... than at international borders. Over the past decade, ePassports, ... travelers to self process through border control via eGates ... number of airports, seaports, and land borders across the ...
(Date:12/11/2014)... 09, 2014 Research and Markets , ... ) has announced the addition of the "Biometrics ... One major trend emerging in this ... biometric systems utilize more than one characteristic of an ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... (OTC,Bulletin Board: BMRX), a leading developer and supplier ... executed an,agreement with Biometric Solutions, LLC, to co-develop ... biometric technology to consumers at,an accelerated rate, growing ... LLC has had successful engineering efforts on,behalf of ...
... are the first to observe the dynamic, ratchet-like movements ... proteins from genetic blueprints. Their study, published ... in the interplay of molecules that allows cells to ... use a variety of tools to build proteins, beginning ...
... of niacin (vitamin B3) in the liver, which should provide ... HDL-cholesterol levels in the blood and thus lower the risk ... levels, the mechanism of how it works has been mysterious, ... production. Recent work had uncovered that a component of ATP ...
Cached Biology News:bioMETRX, Inc. Partners with Biometric Solutions, LLC to Deliver Next Generation Finger Activated Technology 2bioMETRX, Inc. Partners with Biometric Solutions, LLC to Deliver Next Generation Finger Activated Technology 3Researchers observe spontaneous 'ratcheting' of single ribosome molecules 2Researchers observe spontaneous 'ratcheting' of single ribosome molecules 3
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Goat polyclonal to CHMP5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-NKDGVLVDEFGLPQ, corresponding to C terminal amino acids 202-215 of Human CHMP5 Entrez GeneID: ...
... (phospho S207) ( Abpromise for ... Antigen: Synthetic phosphopeptide derived from ... of Serine 207 (V-D-S P -V-A). ... 5608 Swiss ...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Biology Products: